Prelude Therapeutics Incorporat (PRLD) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Prelude Therapeutics Incorporat (PRLD) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Krishna Vaddi (CEO) received $1,348,000 in reported total compensation@if($peoPaid !== null), with $2,423,418 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 67.92.
Other named executives — average
- Average reported total
- $833,563
- Average actually paid
- $1,263,857
Frequently asked questions
- Who is the CEO of PRLD and how much are they paid?
- Krishna Vaddi serves as CEO of Prelude Therapeutics Incorporat. For fiscal year ending December 2025, reported total compensation was $1,348,000.
- What is included in executive compensation?
- SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
- What is pay-versus-performance?
- The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.